Pharma Focus Asia
Eppendorf Bioprocess Solutions

Shuttle Pharma Awarded a New Patent for Selective Inhibitors for Cancer Treatment

Friday, July 30, 2021

Shuttle Pharmaceuticals Holdings, Inc, a Maryland-based developer of new drugs for cancer treatment, was awarded US Patent No.: 11,034,667 B2 for "Selective Histone Deacetylase Inhibitors for the treatment of Human Disease." These non-cytotoxic, highly selective inhibitors target the histone deacetylase 6 (HDAC6) enzyme to stimulate the immune system for applications in the treatment of cancers, neurological diseases and immunological disorders.

Lead inventor Scott Grindrod, PhD describes histone deacetylase (HDAC) inhibitors as "a novel class of drugs that target enzymes involved in regulation of critical cellular functions that can inhibit cancer growth and activate cellular immunity. These are key target functions to improve cancer treatment. HDAC6 regulates the innate immune system and will be tested to activate an anti-cancer immune response to increase the effectiveness of chemotherapy and radiation therapy. The molecules in this patent enhance Shuttle Pharma's platform technology of selective inhibitor discovery for cancer treatment."

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEAMasterControl - Simplify CAPA in 7 StepsTFS - Webinar - DynaSpin™ Single-Use Centrifuge for harvest applicationsMedical Fair Thailand 2023ThermoFisher Scientific - NEW Mobile App3rd ANNUAL COMPUTER SOFTWARE ASSURANCE 2023CPHI & PMEC China 2023Pharma Regulatory Conclave 2023Thermo Fisher Scientific - QualTrak